Contraception in the immediate postnatal period

Key Points

- Contraception
- Family planning
- Progesterone only pill
- Intrauterine device
- Intrauterine system
- Combined oral contraceptive
- Lactational amenorrhoea
- Etonogestrel implant

Version: 1.1
Date Issued: 8 October 2020
Review Date: September 2023
Key words: Contraception, family planning, intrauterine, progesterone

This is a controlled document. If you are using a printed copy, check it against the version on the intranet to ensure you are using the latest edition.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LARC</td>
<td>Long acting reversible contraceptive</td>
</tr>
<tr>
<td>IUD</td>
<td>Intrauterine device</td>
</tr>
<tr>
<td>Cu-IUD</td>
<td>Copper intrauterine device</td>
</tr>
<tr>
<td>LNG-IUS</td>
<td>Levonorgestrel intrauterine system</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>POP</td>
<td>Progesterone only pill</td>
</tr>
<tr>
<td>IUS</td>
<td>Intrauterine system</td>
</tr>
<tr>
<td>TTA</td>
<td>To take away</td>
</tr>
<tr>
<td>FSRH</td>
<td>Faculty of sexual and reproductive healthcare</td>
</tr>
</tbody>
</table>
Contents
1. Purpose of The Guideline..........................................................3
2. Forms of Contraception Available Within The Maternity Department..............................3
3. Follow Up........................................................................5
4. Other Forms Of Contraception ..................................................6
5. Provision of Contraception In The Immediate Postnatal Period........................................7
References..................................................................................8
Appendix One.............................................................................9
Full Version Control Record.......................................................11
1. PURPOSE OF THE GUIDELINE

Effective contraception should be started as soon as possible after childbirth as fertility returns rapidly. FSRH guidance recommends that effective contraception is commenced as soon as possible after delivery by both breastfeeding and non-breastfeeding mothers. This allows individuals to plan any subsequent pregnancy and avoid short inter-pregnancy intervals with their associated poorer pregnancy outcomes.

The most effective long-acting reversible contraceptive (LARC) methods, including the copper IUD, the levonorgestrel-releasing IUS and the etonogestrel implant can be inserted at, or immediately after delivery, in the maternity setting, by appropriately trained maternity staff. LARC methods have the significant advantage of providing immediate, user-independent contraception that is effective for several years without requirement for routine follow up.

2. FORMS OF CONTRACEPTION AVAILABLE WITHIN THE MATERNITY DEPARTMENT

**Copper IUD (Cu-IUD)**

The Cu-IUD can be inserted by an obstetrician or midwife already trained in the technique at the time of caesarean section, immediately after vaginal delivery or at any time up to 48 hours post-partum. If the IUD is not inserted within 48 hours, insertion should be delayed until 4 weeks after the birth to reduce the risk of uterine perforation.

<table>
<thead>
<tr>
<th>Contraindications</th>
<th>Postpartum sepsis, current symptomatic pelvic chlamydia or gonorrhoea infection, current pelvic TB, current gestational trophoblastic disease, current cervical or endometrial cancer, copper allergy, Wilson’s disease. Should not be inserted immediately post-partum if a woman has ruptured membranes for 24 hours or longer, postpartum haemorrhage or chorioamnionitis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potential contraindications include</td>
<td>Previous heavy menstrual bleeding, anaemia (thalassemia, sickle cell disease or iron deficiency); current asymptomatic chlamydia or gonorrhoea infection, complications after organ transplant, long QT syndrome, previous trachelectomy, uterine cavity significantly distorted by fibroids or structural abnormality, HIV infection with CD4&lt;200.</td>
</tr>
<tr>
<td>Contraceptive effectiveness</td>
<td>0.6-0.8% first year contraceptive failure (effective immediately). Enzyme-inducing drugs do not affect contraceptive effectiveness.</td>
</tr>
<tr>
<td>Duration of use</td>
<td>Device-dependent, 5 or 10 years.</td>
</tr>
<tr>
<td>Bleeding</td>
<td>Often heavier, longer, more painful; pattern usually unchanged</td>
</tr>
<tr>
<td>Follow up information required by user</td>
<td>How to check for threads, possibility of long threads, how to access review of pain/bleeding/very long or missing threads, replacement date (5 or 10 years).</td>
</tr>
</tbody>
</table>
**Levonorgestrel intrauterine system (LNG-IUS)**

The 52mg LNG-IUS can be inserted by maternity staff *already trained in the technique* at the time of caesarean section or immediately after vaginal delivery or at any time up to 48 hours post-partum. If the IUD is not inserted within 48 hours, insertion should be delayed until 4 weeks after the birth to reduce the risk of uterine perforation.

<table>
<thead>
<tr>
<th>Contraindications</th>
<th>Allergy to content; postpartum sepsis, current symptomatic chlamydia or gonorrhoea infection, current pelvic TB, current breast, endometrial or cervical cancer, current gestational trophoblastic disease. Should not be inserted immediately postpartum if the woman has had ruptured membranes for 24 hours or longer, chorioamnionitis or postpartum haemorrhage.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potential contraindications include</td>
<td>Current asymptomatic chlamydia or gonorrhoea infection, previous breast cancer, previous arterial thromboembolic event during use, decompensated cirrhosis, hepatocellular adenoma or carcinoma, complications after organ transplant, long QT syndrome, HIV infection with CD4 count &lt;200, uterine cavity significantly distorted by fibroids or structural abnormality, previous tracheectomy.</td>
</tr>
<tr>
<td>Contraceptive effectiveness</td>
<td>0.2% first year contraceptive failure rate (effective immediately if inserted post-partum). Enzyme-inducing drugs do not affect contraceptive effectiveness.</td>
</tr>
<tr>
<td>Duration of use</td>
<td>5 years (for 52mg LNG-IUS)</td>
</tr>
<tr>
<td>Bleeding</td>
<td>Initially erratic, likely to become light over first year of use, may become amenorrhoeic.</td>
</tr>
<tr>
<td>Follow up information required by user</td>
<td>How to check for threads, possibility of long threads, how to access review of pain/bleeding/very long or missing threads, replacement date.</td>
</tr>
</tbody>
</table>
Individuals for whom LARC methods cannot be provided, those that decline LARC and those for whom LARC is unsuitable can be given a 3-month supply of the desogestrel progestogen-only pill (POP) prior to discharge.

**Desogestrel Progesterone only pill (POP)**

The POP is extremely safe and there are few contraindications to its use. The desogestrel POP can be started immediately after delivery (or by Day 21) without any requirement for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days. The POP is highly user-dependent and may not be suitable where there is concern about adherence to pill-taking.

One pill is taken at the same time every day. The pill can be taken up to 12 hours late without affecting contraceptive effectiveness; subsequent pills should be taken at the intended time. If the pill was more than 12 hours overdue, additional contraceptive precautions must be used for 2 days.

<table>
<thead>
<tr>
<th>Contraindications</th>
<th>Allergy to content; current breast cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Potential contraindications include</strong></td>
<td>Previous arterial thromboembolic event during use, previous breast cancer (in the last 5 years), decompensated cirrhosis, hepatic adenoma or adenocarcinoma</td>
</tr>
<tr>
<td><strong>Contraceptive effectiveness</strong></td>
<td>0.3% first year contraceptive failure rate if taken perfectly; 9% with typical use (effective immediately if started by Day 21 post-partum). Enzyme-inducing drugs and conditions that affect GI absorption may affect contraceptive effectiveness.</td>
</tr>
<tr>
<td><strong>Bleeding</strong></td>
<td>Unpredictable.</td>
</tr>
<tr>
<td><strong>Follow up information required by user</strong></td>
<td>How to take, missed pill rules (including after vomiting), possibility of drug interaction, how to access further supplies (including direction to local and online services).</td>
</tr>
</tbody>
</table>

3. **FOLLOW UP**

**Intrauterine contraception**

Women that have had insertion of intrauterine contraception after childbirth require follow up with their GP or family planning nurse to check for and trim threads. If threads are not visible, the woman will require an ultrasound scan to confirm the placement of the device. Additional contraception will be required until the device location is confirmed. They may also require follow up for pain, bleeding, or expulsion. Women are advised to contact their GP to manage these relatively common problems. Clear advice must be provided to users as to how to follow these pathways.

**Progestogen-only pill**

No routine follow up is required after post-partum initiation of the desogestrel progestogen-only pill.
4. OTHER FORMS OF CONTRACEPTION

**Combined hormonal contraception (CHC)**

Contraception is required from Day 21 after childbirth unless the woman is fully breastfeeding and amenorrhoeic. CHC should not be started until 6 weeks after delivery in either breastfeeding women or non-breastfeeding women with additional risk factors for venous thromboembolism (VTE).

Please note: caesarean section is a VTE risk factor. Individuals who are not breastfeeding and have no additional VTE risk factors may consider use of CHC from 3 weeks after childbirth.

There are, however, significant potential health risks associated with use of CHC, therefore prior to provision, medical eligibility must be carefully assessed, blood pressure and BMI measured, and users advised about CHC-associated health risks. CHC will not be offered for immediate postnatal contraception within the maternity department.

**Etonogestrel implant (ENG-IMP)**

The ENG-IMP can be inserted anytime post-delivery. No routine follow up is required after post-partum initiation of the etonogestrel implant. There is a risk of neurovascular injury and migration- therefore women should be advised on how to locate the implants, informed to check this occasionally and report any concerns. If inserted by Day 21 after childbirth, no additional contraceptive precautions are required. This is not currently provided by the maternity department. Women considering ENG-IMP should be provided with a three-month supply of the POP and referred to their GP or local family planning services. No routine follow up is required after post-partum initiation of the etonogestrel implant or desogestrel progestogen-only pill.

There is a risk of neurovascular injury and migration- therefore women should be advised on how to locate the implants, informed to check this occasionally and report any concerns.

**Lactational amenorrhoea**

It is recognised that fully breastfeeding individuals can rely on lactational amenorrhoea for contraception for the first six months after delivery, so long as they remain amenorrhoeic AND continue to breastfeed fully. An individual may, however, reduce breastfeeding or have their first period at any time, with resulting loss of contraceptive effect; this could come at a time when access to contraception services is still restricted by Covid-19. It is recommended, therefore, that breastfeeding individuals commence additional contraception as soon as possible after delivery.

**Female sterilisation**

Existing guidance recommends that, because of concern about potential regret, written consent to female sterilisation at the time of caesarean section should be obtained at least two weeks prior to delivery.
5. PROVISION OF CONTRACEPTION IN THE IMMEDIATE POSTNATAL PERIOD

Community Midwives should discuss contraception with women during their 28 week antenatal appointment. This information should be given in a range of formats including providing women with the Frimley health contraception leaflet and signposting women to maternity website and FSRH guidance.

Women who are having an elective caesarean should be offered the insertion of an IUS/IUD when the caesarean is requested. Consent should be taken for the insertion of the IUS/IUD when women are consented for the caesarean section.

Midwives should discuss contraception as part of the discharge process and women who have not had an IUS/IUD inserted should be offered a 3-month supply of the progesterone only pill.

The obstetric team covering the relevant area of discharge should prescribe a 3-month supply with a TTA letter. The supply from pharmacy should be provided and explained to the woman prior to discharge and she must be informed to contact her GP for further prescriptions. The woman’s GP should be informed of the method of contraception provided as part of the discharge process.
REFERENCES


Appendix one

**How effective are these methods?**
This is the percentage of women who have an unplanned pregnancy with perfect and typical use of each method over one year:

- Progesterone pill: 0.3-9%
- Copper coil: 0.6-0.8%
- Hormonal coil: 0.2%
- Progesterone implant: 0.05%
- Progesterone injection: 0.2-6%
- Combined pill: 0.3-9%
- Lactational amenorrhoea: 2%
- Condoms: 2-18%

**How do I access postnatal contraception?**

- If you would like the progesterone only pill please talk to your midwife or doctor on the postnatal ward. This can be started in hospital.
- If you would like a coil inserted at the time of your caesarean, please discuss this with your doctor who can add this to your consent form.
- If you would like a coil inserted after a vaginal delivery, please discuss this with your doctor on the postnatal ward.
- If you would like the progesterone injection, please talk to your midwife or doctor on the postnatal ward as this can be given before discharge.
- If you would like the progesterone implant, we may need to refer you to a family planning clinic.
- You can also access through your GP or a family planning clinic at a later time.

**For a translation of this leaflet or for accessing this information in another format:**
- Large Print
- Translation
- Audio

**Legal Notice**
Please remember that this leaflet is intended as general information only. We aim to make the information up to date and accurate as possible. Please therefore always check specific advice or any concerns you may have with your doctor.

Frimley Health
NHS Foundation Trust

Obstetrics and Gynaecology
Frimley Health

Contraception after having your baby

Information for patients, relatives and carers
Introduction

Contraception may be the last thing on your mind right now, but did you know that you can get pregnant as early as 3 weeks after giving birth? A short gap between pregnancies is not only exhausting for you but can also increase your risks of complications in pregnancy and the risk of the baby not growing well. We have put together this information leaflet to give you an idea of the contraceptive options available to you (all offered methods are reversible). If you are interested, please ask your midwife or doctor for further information.

What are your options?

- Progestrone only pill
- Progesterone implant
- Progesterone injection
- Combined oral contraceptive pill

You can also use:

- Barrier methods (condoms, caps and diaphragms)
- Natural family planning: tracking your cycle to work out fertile times or lactation amenorrhoea if breastfeeding.

Desogestrel progestrone only pill (Mini-pill)

One pill taken at the same time each day. It is suitable for most women and can be started straight after birth. It works by thickening the cervical mucus and sometimes prevents ovulation. It can be associated with irregular bleeding although this usually settles with time. Many women have no periods at all when taking this pill. Breastfeeding is not affected.

Copper intrauterine device (Copper coil)

The copper coil can provide contraception for 5-10 years. The copper causes an immune reaction within the womb which is toxic to sperm. It is not toxic to anything else in your body. It is a good option for women wanting to avoid hormones, although it can make your periods heavier and more painful. It can be inserted at the time of caesarean section or within 2 days after 4 weeks of a vaginal delivery. Breastfeeding is not affected.

Hormonal intrauterine system (Hormonal coil)

The hormonal coil can provide contraception for up to 5 years. It slowly releases a form of progestrone that thins the lining of the womb. The most common side effect is irregular bleeding although this usually settles with time. Many women report their periods being lighter or stopping whilst they have a hormonal coil. It can be inserted at the time of caesarean section or within 2 days after 4 weeks of a vaginal delivery. Breastfeeding is not affected.

Progestrone implant

The implant is a small rod inserted under the skin of your upper arm and provides contraception for up to 3 years. It slowly releases small amounts of progesterone which thins the lining of the womb and may stop ovulation. It can be inserted any time after birth. It can be associated with irregular bleeding although this usually settles with time. Many women stop having periods at all. Breastfeeding is not affected.

Progestogen injections

This is a single injection into the buttock area every 10-12 weeks. It works by thinning the lining of the womb and stopping ovulation. It can be given any time after birth. It can be associated with irregular bleeding although this usually settles with time and many women stop having periods at all. Breastfeeding is not affected.

Combined Oral Contraceptive pill

One pill taken at the same time each day for 3 weeks, followed by a week break. It works by preventing ovulation. Periods are usual regular and light. Not suitable for women who are breastfeeding (other contraindications also apply). Can be started 3 weeks after delivery if suitable.

Can you rely on breastfeeding as contraception?

Lactational amenorrhoea can provide a level of contraception but only if the following conditions are all met:

- It has been six months or less since the birth of your baby
- You are exclusively breastfeeding (no formula)
- Time between feeds not more than 4 hours in the day and 6 hours at night
- Your periods have not returned

Giving your baby expressed breast milk may reduce the effectiveness of lactational amenorrhoea as contraception.
Full version control record

Version: 1.1
Guidelines Lead(s): Nicola Rose-Stone (Consultant Midwife – secondment)

Contributor(s): Helen Walker (Consultant)
Lead Director / Chief of Service: Anne Deans (Chief of Service)
Library check completed: Obstetrics and Gynaecology Clinical Governance Committee, 30th September 2020
Ratified at: None
Date Issued: 8 October 2020
Review Date: September 2023
Pharmaceutical dosing advice and formulary compliance checked by: Ruhena Ahmad (Lead pharmacist for Women and Children)
Key words: Contraception, family planning, intrauterine, progesterone

This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date. This guideline is for use in Frimley Health Trust hospitals only. Any use outside this location will not be supported by the Trust and will be at the risk of the individual using it.

Version Control Sheet

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Guideline Lead(s)</th>
<th>Status</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>September 2020</td>
<td>Nicola Rose-Stone (Consultant midwife – secondment)</td>
<td>Final</td>
<td>First cross site version</td>
</tr>
<tr>
<td>1.1</td>
<td>July 2022</td>
<td>Nicola Rose-Stone (Consultant midwife)</td>
<td>amendment</td>
<td>Contraception leaflet added as appendix 1 and transferred to new Clinical Guidelines Template.</td>
</tr>
</tbody>
</table>

Related Documents

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Document Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy</td>
<td>Medicines Policy</td>
</tr>
<tr>
<td>Patient Leaflet</td>
<td>Contraception after Having your Baby</td>
</tr>
</tbody>
</table>